10QSB 1 form10-qsb.htm SEQUIAM CORPORATION 10-QSB 9-30-2006 Sequiam Corporation 10-QSB 9-30-2006



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

x
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2006

OR

o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______________to _______________.

Commission File Number 333-45678
 
 
SEQUIAM CORPORATION
(Exact name of small business issuer as specified in its charter)

California
(State or other jurisdiction of incorporation or organization)
33-0875030
(I.R.S. Employer Identification No.)

300 Sunport Lane, Orlando, Florida 32809
(Address of principal executive offices)
 
407-541-0773
(Issuer’s telephone number)

 
(Former name, former address and former fiscal year if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for the such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  x     No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o      No x

The number of shares of the Registrant’s Common Stock outstanding as of October 27, 2006 was 81,344,488.

Transitional Small Business Disclosure Format (Check one): Yes o     No x




 

FORM 10-QSB

INDEX

 
Page
 
 
PART I: FINANCIAL INFORMATION
3
 
 
ITEM 1. FINANCIAL STATEMENTS
3
 
 
Condensed Consolidated Balance Sheets (Unaudited)
3
 
 
Condensed Consolidated Statements of Operations (Unaudited)
4
 
 
Condensed Consolidated Statements of Cash Flows (Unaudited)
5
 
 
Notes to Condensed Consolidated Financial Statements (Unaudited)
7
 
 
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
14
 
 
ITEM 3. CONTROLS AND PROCEDURES
18
 
 
PART II. OTHER INFORMATION
19
 
 
ITEM 1. LEGAL PROCEEDINGS
19
   
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
19
   
ITEM 6. EXHIBITS
19
 
 
SIGNATURES
20



Introductory Note
Caution Concerning Forward-Looking Statements

This Report and our other communications and statements may contain “forward-looking statements,” including statements about our beliefs, plans, objectives, goals, expectations, estimates, projections and intentions. These statements are subject to significant risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. The words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements. All forward-looking statements, by their nature, are subject to risks and uncertainties. Our actual future results may differ materially from those set forth in our forward-looking statements. For information concerning these factors and related matters, see Item 2, “Management’s Discussion and Analysis,” in this Report, and the following sections of our Annual Report on Form 10-KSB for the year ended December 31, 2005: (a) “Risk Factors” in Item 6, “Management’s Discussion and Analysis,” and (b) “Introduction” in Item 6, “Management’s Discussion and Analysis.” However, other factors besides those referenced could adversely affect our results, and you should not consider any such list of factors to be a complete set of all potential risks or uncertainties. Any forward-looking statements made by us herein speak as of the date of this Quarterly Report. We do not undertake to update any forward-looking statement, except as required by law.

 

2



 
PART I: FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Sequiam Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
 
 
 
September 30, 2006 (Unaudited)
 
December 31, 2005
 
Assets
 
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
 
Cash
 
$
25,759
 
$
763,197
 
Receivables, net
 
 
213,004
 
 
180,892
 
Inventory
 
 
857,982
 
 
78,531
 
Total current assets
 
 
1,096,745
 
 
1,022,620
 
Property and equipment, net
 
 
991,706
 
 
1,108,255
 
Intellectual properties, net
 
 
622,238
 
 
809,177
 
Product development costs
 
 
352,091
 
 
174,130
 
Loan costs, net
 
 
-
 
 
253,098
 
Receivables
 
 
-
 
 
75,000
 
Deposits and other assets
 
 
141,737
 
 
51,142
 
Total assets
 
$
3,204,517
 
$
3,493,422
 
 
 
 
 
 
 
 
 
Liabilities and shareholders’ deficit
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
 
Notes payable
 
$
-
 
$
33,055
 
Accounts payable
 
 
805,967
 
 
295,989
 
Accrued expenses
 
 
593,633
 
 
528,496
 
Deferred revenue
   
43,000
   
-
 
Deferred rents
 
 
36,735
 
 
37,231
 
Current portion of long-term debt
 
 
3,678,899
 
 
1,053,016
 
Loans from shareholders
 
 
62,000
 
 
473,648
 
Accrued shareholders’ salaries
 
 
-
 
 
1,539,792
 
Total current liabilities
 
 
5,220,234
 
 
3,961,227
 
Long-term debt
 
 
925,649
 
 
3,868,411
 
Loans from shareholders
   
411,000
   
-
 
Mandatorily redeemable cumulative convertible preferred stock
 
 
-
 
 
598,281
 
Total liabilities
 
 
6,556,883
 
 
8,427,919
 
Shareholders’ deficit:
 
 
 
 
 
 
 
Preferred shares
   
108,921
   
-
 
Common shares
 
 
80,402
 
 
64,458
 
Additional paid-in capital
 
 
20,873,286
 
 
12,883,563
 
Accumulated deficit
 
 
(24,421,570
)
 
(17,879,518
)
Accumulated other comprehensive income (loss)
 
 
6,595
 
 
(3,000
)
Total shareholders’ deficit
 
 
(3,352,366
)
 
(4,934,497
)
Total liabilities and shareholders’ deficit
 
$
3,204,517
 
$
3,493,422
 
 
See accompanying notes to condensed consolidated financial statements.


 

3



 
Sequiam Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)

 
For the Three Months Ended September 30,
For the Nine Months Ended September 30,
 
2006
2005
2006
2005
         
Revenues
       
Services
$ 28,198
$ 206,143
$ 85,909
$368,747
Product sales
232,371
116,700
442,565
152,472
         
Total revenues
260,569
322,843
528,474
521,219
         
Costs and expenses:
       
Cost of services
27,221
154,577
82,292
450,928
Cost of product sales
254,714
130,164
512,873
234,922
Selling, general and administrative
674,434
511,488
2,678,292
2,321,548
Gain on sale of equipment
-
-
(5,000)
(370)
Loss on impairment of intellectual properties
-
154,469
-
154,469
Gain on restructuring of debt
-
-
(13,055)
-
Loss on settlement of lawsuit
-
-
200,000
-
 
956,369
950,698
3,455,402
3,161,497
         
Loss from operations
(695,800)
(627,855)
(2,926,928)
(2,640,278)
         
Interest expense
(846,927)
(181,985)
(2,320,012)
(901,359)
         
Net loss
(1,542,727)
(809,840)
(5,246,940)
(3,541,637)
Preferred stock dividends
(74,671)
-
(108,918)
-
Net loss applicable to common stock
$(1,617,398)
$(809,840)
$(5,355,858)
$(3,541,637)
Net loss per common share:
       
Basic and diluted
$(0.02)
$(0.01)
$(0.08)
$(0.06)
         
Shares used in computation of net loss per common share - Basic and diluted weighted average shares outstanding
77,176,832
62,337,353
70,668,864
55,823,443
         
         
         
See accompanying notes to condensed consolidated financial statements

 

4

Sequiam Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
 
 
Nine months ended September 30,
 
 
2006
 
2005
 
Cash flows from operating activities:
 
 
 
 
 
 
 
Net loss
 
$
(5,246,940
)
$
(3,541,637
)
Adjustments to reconcile net loss to net cash
used for operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
 
 
390,936
 
 
390,361
 
Accretion of debt discount
 
 
1,503,378
 
 
485,228
 
Amortization of loan costs
 
 
253,098
 
 
224,252
 
Amortization of product development costs
 
 
14,539
 
 
-
 
Issuance of common stock in exchange for services and interest
 
 
314,710
 
 
520,622
 
Issuance of common stock in exchange for salaries
 
 
282,269
 
 
344,536
 
Issuance of stock options to employees
 
 
34,246
 
 
-
 
Gain on sale of equipment
   
(5,000
)
 
-
 
Loss on impairment of intellectual properties
   
-
   
154,469
 
Gain on restructuring of debt
 
 
(13,055
)
 
-
 
(Increase) decrease in receivables
 
 
20,756
 
 
(140,952
)
Increase in allowance for bad debts
 
 
22,132
 
 
-
 
Increase in inventory
 
 
(779,451
)
 
-
 
(Increase) decrease in prepaid expenses, deposits and other assets
 
 
(90,595
)
 
70,122
 
Decrease in bank overdraft
 
 
-
 
 
(24,165
)
Increase (decrease) in deferred revenue
 
 
43,000
 
 
(6,000
)
Increase (decrease) in accounts payable
 
 
509,978
 
 
(162,626
)
Increase in accrued expenses
 
 
65,137
 
 
180,331
 
Increase (decrease) in deferred rents
 
 
(496
 
10,929
 
Increase in accrued shareholders’ salaries
 
 
-
 
 
170,000
 
Net cash used for operating activities
 
 
(2,681,358
)
 
(1,324,530
)
 
 
 
 
 
 
 
 
Cash flows from investing activities:
 
 
 
 
 
 
 
Proceeds from sale of equipment
   
5,000
   
-
 
Equipment purchases
 
 
(87,448
)
 
(288
)
Purchase of intellectual properties
   
-
   
(650
)
Product development costs capitalized
 
 
(192,500
)
 
(158,308
)
Net cash used for investing activities
 
 
(274,948
)
 
(159,246
)
 
 
 
 
 
 
 
 
Cash flows from financing activities:
 
 
 
 
 
 
 
Proceeds from sale of common stock and exercise of warrants
 
 
250,000
 
 
436,619
 
Proceeds from sale of preferred stock
   
2,962,500
   
-
 
Payment of stock issuance costs
   
(347,181
)
 
-
 
Repayment of notes payable
 
 
(20,000
)
 
(47,804
)
Proceeds from long-term debt
   
-
   
2,100,000
 
Repayment of long-term debt
 
 
(635,398
)
 
(1,055,000
)
Proceeds from shareholder loans
 
 
-
 
 
366,761
 
Repayment of shareholder loans
 
 
(648
)
 
(14,501
)
Net cash provided by financing activities
 
 
2,209,273
 
 
1,786,075
 
Effect of exchange rate changes on cash
 
 
9,595
 
 
-
 
Net increase (decrease) in cash
 
 
(737,438
)
 
302,299
 
Cash, beginning of period
 
 
763,197
 
 
-
 
Cash, end of period
 
$
25,759
 
$
302,299
 
See accompanying notes to condensed consolidated financial statements.
 
5



 
Sequiam Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)
 

 
 
Nine months ended
September 30,
 
 
 
2006
 
2005
 
Supplemental disclosures of non-cash investing and financing activities:
 
 
 
 
 
 
 
               
Preferred stock dividend unpaid at end of period
 
$
108,918
 
$
-
 
Common shares issued upon conversion of mandatorily redeemable cumulative
convertible preferred stock
 
 
 
1,575,000
 
 
-
 
Common shares issued for payment of accrued shareholders’ salaries
 
 
1,539,792
 
 
-
 
Beneficial conversion feature of preferred stock
 
 
1,295,112
 
 
-
 
Notes payable and long-term debt converted to common stock
 
 
-
 
 
993,182
 
Discount on debt
 
 
-
 
 
813,837
 
Common shares issued for acquisition of Constellation Biometrics Corporation
 
 
-
 
 
175,000
 
 

See accompanying notes to condensed consolidated financial statements.


6


Sequiam Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Note 1 - Description of Business

Sequiam Corporation (“Sequiam” or the “Company”) through its wholly owned subsidiaries, primarily develops, markets, and supports a portfolio of biometric fingerprint unlocking devices that enable users to gain access using their personal identity. The Company also develops, markets and supports Internet and print enterprise-wide software products that enable users to acquire, manage, personalize, and present information. In addition, the Company provides application service provider hosting of internet-enabled solutions, internet service provider services including internet access and hosting, consulting, application integration, custom web development and software development services.

The Company's operations are divided into two distinct operating segments: Safety and Security and Information Management. The Safety and Security segment includes the Company’s biometric technology products. The Information Management segment includes all non-biometric technology products.
 
The Company's condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced net losses since inception, which have caused a working capital deficit and an accumulated deficit of approximately $4,123,000 and $24,422,000, respectively, as of September 30, 2006. In addition, the Company has consumed cash in its operating activities of approximately $2,681,000 and $1,325,000 for the nine months ended September 30, 2006 and 2005, respectively. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.
 
Management has been able, thus far, to finance the losses, as well as the growth of the business, primarily through debt and stock offerings. The Company is continuing to seek other sources of financing and attempting to increase revenues within its core business of biometric security products. There are no assurances that the Company will be successful in achieving its goals.
 
In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company cannot continue as a going concern.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

The Company, under the rules and regulations of the Securities and Exchange Commission, has prepared the unaudited condensed consolidated financial statements. The accompanying condensed consolidated financial statements contain all normal recurring adjustments, which are, in the opinion of management, necessary for the fair presentation of such financial statements. Certain information and disclosures normally included in the financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted under such rules and regulations although the Company believes that the disclosures are adequate to make the information presented not misleading. The year-end balance sheet data was derived from the audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes for the Company included in Form 10-KSB filed for the year ended December 31, 2005. Interim results of operations for the periods presented may not necessarily be indicative of the results to be expected for the full year.

Net Loss per Common Share

Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted loss per common share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options, adjusted for the assumed repurchase of the Company’s common stock, at the average market price, from the exercise proceeds and also may include incremental shares issuable in connection with convertible securities. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. As of September 30, 2006, the Company had 75,960,721 potentially dilutive common shares as a result of warrants and options granted and convertible preferred stock issued.


7

 
 
Principles of Consolidation

The consolidated financial statements include the accounts of the Sequiam Corporation and its subsidiaries. All intercompany transactions and accounts have been eliminated.
 
Accounting for Stock-Based Compensation

At September 30, 2006, the Company has two stock-based compensation plans (the “Plans”) which are described more fully in Note 7. Prior to January 1, 2006, the Company accounted for the Plans under the recognition and measurement provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”), and related Interpretations, as permitted by Financial Accounting Standards Board (“FASB”) Statement No. 123, “Accounting for Stock-Based Compensation”. No stock-based compensation cost related to the Plans was recognized in the Statement of Operations for the nine months ended September 30, 2005, as all options granted under the Plans had an exercise price at least equal to the market value of the underlying common stock on the date of grant.

Effective January 1, 2006, the Company adopted the fair value recognition provisions of FASB Statement No. 123(R) “Share-Based Payment”, using the modified-prospective transition method. Under that transition method, compensation cost recognized includes (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of Statement 123, and (b) compensation cost for all share-based payments granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of Statement 123(R). Accordingly, results for prior periods have not been restated.

As a result of adopting Statement 123(R) on January 1, 2006, the Company’s net loss for the nine months ended September 30, 2006 was $34,246 higher than if it had continued to account for share-based compensation under APB 25. Basic and diluted net loss per common share for the nine months ended September 30, 2006 would have remained $0.08 if the Company had not adopted Statement 123(R). Also, there was no change in cash used in operating activities and cash provided by financing activities as a result of adopting Statement 123(R).

There would be no change in the net loss and net loss per common share for the three months and nine months ended September 30, 2005 if the Company had applied the fair value recognition provisions of Statement 123 to options granted under the Plans for this period. There was no share-based employee compensation cost included in net loss as reported for these periods. No share-based employee compensation cost would have been included in net loss for these periods if the fair value based method had been applied to all awards.

Note 3 - Loans from Shareholders

On May 17, 2006, the Company entered into Amended and Restated Promissory Notes with Nicholas VandenBrekel, the Company’s CEO, and Mark Mroczkowski, the Company’s CFO, for $361,000 and $50,000, respectively. Each note is for a term of eighteen months, bears interest at 6%, is unsecured and replaces demand notes previously issued in 2002 for the same amounts.

Note 4 - Inventory

Inventory consists of the following at:

 
 
September 30, 2006
 
December 31,  2005
Raw materials
 
$
549,141
 
$
78,531
Finished goods
 
 
308,841
 
 
-
 
 
 $
857,982
 
 $
78,531

Note 5 - Preferred Stock

On May 17 and June 21, 2006, the Company closed preferred stock transactions with a total of nineteen institutional and accredited investors, (collectively the “Purchasers”) pursuant to which the Company issued a total of 2,962.5 shares of its Series B preferred stock, par value $0.001 per share (the “Preferred Stock”) with a stated per share value of $1,000 for total proceeds of $2,962,500 (the “Offering”).

The Preferred Stock is non-voting and entitles the Purchasers to receive a 10% cumulative dividend payable semiannually. The Preferred Stock is convertible into 14,107,142 common shares of the Company at a fixed price of $0.21 per share.

In connection with the Offering, the Purchasers received warrants to purchase up to an aggregate 14,107,142 shares of the Company’s common stock at $0.30 per share (the “Series B Warrants”).

8

All stock conversion prices and exercise prices are subject to adjustment for stock splits, stock dividends or similar events. The Company also agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the shares issuable upon the conversion of the Preferred Stock and exercise of the Series B Warrants.

A fair value of $1,667,388 has been assigned to the Series B Warrants. Also, as a result of the Preferred Stock transaction, a preferred stock conversion feature of $1,295,112 and stock issuance costs of $347,181 were recorded. The Company’s accumulated deficit increased by $1,295,112 as a result of this preferred stock conversion feature being recorded.

Note 6 - Capital Stock

During the nine months ended September 30, 2006, the following activity occurred related to the Company’s capital stock:

The Company received $150,000 and in exchange issued 483,871 of its common shares pursuant to Regulation S of the Securities Act of 1933, as amended.

During April 2006, the Company entered into an Amendment to a Promissory Note (the “Amendment”). This Promissory Note was classified as a loan from shareholder prior to it being repaid during 2005. As part of the Amendment, it was agreed that for certain consideration provided by the Promissory Note holder, the warrant to purchase 7,500 of the Company’s common shares at $1.00 per share granted under the original Promissory Note was amended to 476,191 of the Company’s common shares at $0.21 per share. As a result of the Amendment, the Company recognized $101,970 of interest expense, representing the difference between the fair values of the amended and original warrants. During April 2006, this warrant was exercised and the Company received $100,000 and in exchange issued 476,191 of its common shares.

Effective May 17, 2006, the Company, entered into two Restricted Stock Agreements (the “Agreements”) with Nicholas VandenBrekel and Mark Mroczkowski, the Company’s CEO and CFO, respectively. The purpose of the Agreements was to convert accrued salaries and interest owed to the officers into restricted common shares. In consideration of accrued and unpaid salary of $799,690 owed to Nicholas VandenBrekel and $740,102 owed to Mark Mroczkowski under the terms of their Amended and Restated Employment Agreements, together with interest thereon in the amount of $116,384 and $108,002, respectively, the Company issued 3,664,296 shares and 3,392,416 shares to them, based on the conversion price of $0.25 per share of the Company's common stock, subject to certain restrictions thereon (collectively, the “Restricted Shares”). In the Company’s opinion, the issuance and sale of the Restricted Shares were exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance upon Section 4(2) of the Securities Act.

The Company issued 7,500,000 of its common shares pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended, as a result of elections made by holders of the Company’s mandatorily redeemable cumulative convertible preferred stock to convert shares of the Company’s Series A preferred stock to shares of the Company’s common stock, at a fixed conversion rate of $0.21 per share. Also, the Company issued 427,297 of its common shares pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended, to the holders of the Company’s mandatorily redeemable cumulative convertible preferred stock as payment of the 9% cumulative dividend payable to Series A preferred stockholders.

In connection with the Company’s mandatorily redeemable cumulative convertible preferred stock transaction with seven institutional investors (collectively the “Purchasers”) that closed on November 30, 2005, the Purchasers received warrants (the “Warrants”) to purchase up to an aggregate of 7,500,000 shares of the Company’s common stock at $0.33 per share. The re-set provision of the Warrants was affected by the Series B preferred stock transaction described in Note 5. As a result, the exercise price of the Warrants has decreased from $0.33 to $0.21 and the number of warrants held by the Purchasers has been increased in accordance with the anti-dilution provisions of the Warrants. Because of the change in the exercise price of the Warrants, the preferred stock discount initially recorded when the Warrants were issued was increased by $106,170 which was charged to interest expense during the nine months ended September 30, 2006.

Note 7 - Stock Incentive Plans

On September 23, 2003 Sequiam executed the Sequiam Corporation 2003 Employee Stock Incentive Plan and the Sequiam Corporation 2003 Non-Employee Directors And Consultants Stock Plan (the “Plans”). These Plans are intended to allow designated officers, directors (including non-employee directors), employees and certain non-employees, including any independent contractor or consultant providing services to the Company and its Subsidiaries to receive certain options (the “Stock Options”) to purchase Sequiam common stock, par value $0.001 per share, and to receive grants of the common stock subject to certain restrictions.   The maximum number of shares of the common stock that may be issued pursuant to the Plans shall be 14,000,000 and 1,000,000, respectively at September 30, 2006.

The Company may grant Stock Options in such amounts, at such times, and to the employees nominated by the management of the Company in its discretion. Stock Options granted under the Plans shall constitute “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986 as amended.

9

The purchase price (the “Exercise Price”) of shares of the common stock subject to each Stock Option shall be the fair market value of the common stock on the date the Stock Option is granted; provided, however, for designated non-statutory stock options, the Board of Directors may determine an Exercise Price at, above or below fair market value. For an employee holding greater than 10 percent of the total voting power of all stock of the Company, either common or preferred, the Exercise Price of an incentive stock option shall be at least 110 percent of the fair market value of the common stock on the date of the grant of the option.
 

As of September 30, 2006, no Stock Options and 250,000 shares of common stock had been granted under the Sequiam Corporation 2003 Non-Employee Directors and Consultants Stock Plan.

A summary of Stock Option activity under the 2003 Employee Stock Incentive Plan as of September 30, 2006, and changes during the period then ended is presented below:
Options
 
Number
of Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining  
Contractual
Term
 
 
Aggregate Intrinsic
Value
 
Outstanding at January 1, 2006
 
 
9,451,000
 
$
0.186
 
 
 
 
 
 
 
Granted
 
 
550,000
 
$
0.180
 
 
 
 
 
 
 
Exercised
 
 
-0-
 
 
-0-
 
 
 
 
 
 
 
Canceled
 
 
(115,500
)
$
0.170
 
 
 
 
 
 
 
Outstanding at September 30, 2006
 
 
9,885,500
 
$
0.186
 
 
7.2
 
 
-0-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vested or expected to vest at September 30, 2006
 
 
9,885,500
 
$
0.186
 
 
7.2
 
 
-0-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable at September 30, 2006
 
 
9,527,167
 
$
0.186
 
 
7.2
 
 
-0-
 

The fair value of Stock Options granted during 2006 was calculated utilizing the following weighted-average assumptions: no dividend yield; expected volatility of 165.17% (calculated using historical volatility); risk-free interest rate of 4.02%; and expected term of 10 years. The fair value of each Stock Option is estimated on the date of grant using the Black-Scholes option-pricing model.

The weighted-average grant-date fair value of Stock Options granted was $98,271.

As of September 30, 2006, there was $64,025 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plans. That cost is expected to be recognized over a weighted-average period of 1.3 years.

As of September 30, 2006, no common stock had been granted under the Sequiam Corporation 2003 Employee Stock Incentive Plan.

Note 8 - Commitments and Contingencies

Effective April 10, 2006, Sequiam Biometrics, Inc., a wholly-owned subsidiary of the Company, entered into an Exclusive License Agreement (the “Tacoma Agreement”) with Tacoma Technology, Inc. (“Tacoma”). The purpose of the Tacoma Agreement is to provide the conditions and terms for the manufacturing and distribution of certain biometric products of Tacoma, including all of Tacoma’s biometric sensor modules. The term of the Tacoma Agreement is six years and may be automatically renewed for additional 24-month terms unless either party provides the other with 30-days prior notice of its desire not to renew.

Effective April 15, 2006, Sequiam Biometrics, Inc. (“Biometrics”), a wholly-owned subsidiary of the Company, entered into an Exclusive Distribution and Manufacturing Agreement (the “Agreement”) with CJCC (China Jiangsu Construction Corporation). The purpose of the Agreement is to provide the conditions and terms for the distribution of certain biometric products and services of Biometrics (the “Products”), including a biometric personal digital assistant.

In connection with the Agreement, CJCC will act, during the term of the Agreement, as the exclusive distributor of Products in Asia for Biometrics. In addition, Biometrics will act, during the term of the Agreement, as the exclusive biometric designer and manufacturer of the Products for CJCC.

10

As part of the Agreement, CJCC purchased 483,871 restricted common shares of Sequiam Corporation common stock at full market value during the nine months ended September 30, 2006.

The term of the Agreement is five years, expiring on April 15, 2011, and may be renewed for additional 24-month terms unless either party provides the other with written notice of termination at least 90-days prior to the expiration of the then current term.

On April 24, 2006, in the case of Xerox Corporation vs. Brekel Group, Inc. in the Circuit Court in and for Pinellas County, State of Florida, Xerox Corporation and Sequiam Sports, Inc. (formerly known as Brekel Group, Inc.), a wholly-owned subsidiary of Sequiam Corporation, gave joint notice of voluntary dismissal with prejudice of this matter with each party bearing its own costs and attorney fees.

On or about October 3, 2002, General Electric Capital Corporation (“GE”) filed a lawsuit against Brekel Group, Inc. (“Brekel”), who the Company acquired during 2002, in the Circuit Court of the 9th Judicial Circuit in and for Orange County, located in Orlando, Florida. GE claimed that Brekel owed a deficiency balance in the amount of $93,833 for three digital copiers rented under a lease agreement. Brekel had returned possession of the copiers to GE, but Brekel disputed the claim for damages. On January 30, 2004 Brekel entered into a settlement agreement with GE by agreeing to pay $70,000 in 36 monthly installments of $1,945 without interest. On April 27, 2006, GE’s successor in interest TBF Financial, LLC agreed to settle the remaining outstanding balance for $20,000, which was paid during May 2006. As a result, a gain on restructuring of debt of $13,055 was recorded for the nine months ended September 30, 2006.
 
On April 27, 2006, Sequiam Biometrics, Inc., a wholly owned subsidiary of the Company, entered into a Joint Venture Agreement (the “JV Agreement”) with Changjiang Computer Group Corporation (“CJCGC”) and Magstone Innovation, Inc. (“Magstone”). The name of the Joint Venture is Shanghai Changjiang Intelligence Information Technology, LTD (the “JV”). The JV is headquartered in Shanghai. The purpose of the JV Agreement is to develop and market biometric and other IT products and applications in China and other regions and to support Biometrics by providing research and development for new products. The JV Agreement grants Biometrics exclusive rights to distribute those products in North America, Europe and Africa.

The JV is owned 30% each by Biometrics and Magstone and 40% by CJCGC. The JV Agreement was subject to Chinese government approval, which occurred during the quarter ended September 30, 2006.

As part of the JV Agreement, Biometrics and Magstone must invest $60,000 each and CJCGC $80,000. The Company made this investment subsequent to September 30, 2006. The term of the JV Agreement is twenty years, expiring on May 31, 2026, and will be automatically renewed for additional ten-year terms unless all parties agree in writing to cease operations prior to the expiration of the then current term.

The Company accounts for its investment in the JV under the equity-method of accounting.
 
The Company currently operates without directors’ and officers’ insurance and is at risk for those types of losses.

As a result of not obtaining consent from one Series A preferred stockholder to enter into the Amendment to a Promissory Note discussed in Note 6, that preferred stockholder had the right to require the Company to redeem all of the Series A preferred stock held by them for a redemption price, in cash, equal to the triggering redemption amount as defined in the Certificate of Determination of Preferences, Rights and Limitations of Series A 9% Convertible Preferred Stock. On August 31, 2006, the Company obtained consent from this Series A preferred stockholder. As a result, the Company effectively cured its default and is no longer under any obligation to redeem any of the Series A preferred stockholder’s preferred stock.

Effective July 6, 2006, Sequiam Biometrics, Inc. (“Biometrics”), a wholly-owned subsidiary of the Company, entered into a Distribution and Manufacturing Agreement (the “Agreement”) with Quasar Group, Inc. (“Quasar”). The purpose of the Agreement is to set out the terms and conditions of the distribution of certain biometric products and services of Biometrics (the “Products”). Also, as part of the Agreement, Biometrics and Quasar agreed to form a new corporation (“Distributor”) in Switzerland. Biometrics will own 51% and Quasar will own 49% of Distributor.
 
Distributor agrees to purchase from Biometrics, during the term of the Agreement, all of its requirements as needed for the Products for sale in Europe and the Middle East. In addition, Biometrics will act, during the term of the Agreement, as the exclusive biometric designer and manufacturer of the Products for Distributor.
 
11

As part of the Agreement, and as a prerequisite of the Distributor obtaining a Swiss canton-sponsored loan in connection with the Swiss Bonny Decree program, a program sponsored by the Swiss Confederation available to companies which make innovative and economically significant investments and are located in economically-threatened areas, Biometrics and Quasar will demonstrate that the Distributor will have a minimum of $1,500,000 in intangible assets. Distributor will use its best effort to secure a loan via the Swiss Bonny Decree program in an amount equal to three million Swiss francs (approximately $2,400,000 as of September 30, 2006), which will be Quasar’s sole responsibility. Pursuant to the Bonny Decree program, the loan will have an annual interest rate corresponding to the standard commercial credit interest rate in Switzerland and will be amortized over a period no longer than ten years. The loan should have a payment grace period of no less than two years.
 
The term of the Agreement is ten years, expiring on July 6, 2016, and may be renewed for additional 24-month terms unless either party provides the other with written notice of termination at least twelve months prior to the expiration of the then current term.
 
On July 13, 2006, the Company reached an agreement with Chapman Spira & Carson, LLC (“Chapman”) to settle the complaint filed by Chapman on or about September 28, 2005 in United States District Court for the Southern District of New York in which Chapman asserted claims for breach of contract and unjust enrichment (the “Dispute”). The agreement to settle the Dispute required the Company to deliver a cash payment to Chapman of $200,000, which was made in July 2006. As a result, the Company recorded a loss on settlement of lawsuit of $200,000 during the nine months ended September 30, 2006. In exchange for the settlement payment, both parties stipulated and agreed that all claims and counterclaims in the Dispute are discontinued as to all parties with prejudice. Neither party admitted any liability or wrongdoing and the settlement did not construe any admission of liability or wrongdoing.
 
Note 9 - Operating Segments

Pursuant to FAS 131, the Company defines an operating segment as:

·  A business activity from which the Company may earn revenue and incur expenses;

·  Whose operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and

·  For which discrete financial information is available.

The Company has two operating segments, which are defined as each business line that it operates. This however, excludes corporate headquarters, which does not generate revenue.

The Company’s operating segments are defined as follows:

The Safety and Security segment provides fingerprint biometric access control systems technology and fingerprint identification technology.

The Information Management segment provides interactive web-based technologies, as well as ASP, ISP and other customer web development and software development services.

The table below presents certain financial information by business segment for the quarter ended September 30, 2006.
 
 
Safety and Security
 
Information Management
 
Segments Total
 
Corporate
 
Consolidated Total
 
Revenue from external customers
 
$
232,371
 
$
28,198
 
$
260,569
 
 
-
 
$
260,569
 
Interest expense
 
 
-
 
 
-
 
 
-
 
 
(846,927
)
 
(846,927
)
Depreciation and amortization
 
 
(75,487
)
 
(16,211
)
 
(91,698
)
 
(42,613
)
 
(134,311
)
Segment loss
 
 
(287,175
)
 
(40,982
)
 
(328,157
)
 
(1,214,570
)
 
(1,542,727
)
Segment assets (1)
 
 
2,237,539
 
 
202,126
 
 
2,439,665
 
 
764,852
 
 
3,204,517
 
   
(1)
Segment assets have been adjusted for intercompany accounts to reflect actual assets for each segment.

12

 
 
Safety and Security
 
Information Management
 
Segments Total
 
Corporate
 
Consolidated Total
 
Revenue from external customers
 
$
442,565
 
$
85,909
 
$
528,474
 
 
-
 
$
528,474
 
Interest expense
 
 
-
 
 
(2,256
)
 
(2,256
)
 
(2,317,756
)
 
(2,320,012
)
Depreciation and amortization
 
 
(215,366
)
 
(48,297
)
 
(263,663
)
 
(127,273
)
 
(390,936
)
Segment loss
 
 
(912,399
)
 
(139,677
)
 
(1,052,076
)
 
(4,194,864
)
 
(5,246,940
)
 
The table below presents certain financial information by business segment for the quarter ended September 30, 2005.

 
 
Safety and Security
 
Information Management
 
Segments Total
 
Corporate
 
Consolidated Total
 
Revenue from external customers
 
$
116,700
 
$
206,143
 
$
322,843
 
 
-
 
$
322,843
 
Interest expense
 
 
-
 
 
(1,850
)
 
(1,850
)
 
(180,135
)
 
(181,985
)
Depreciation and amortization
 
 
(66,863
)
 
(73,620
)
 
(140,483
)
 
-
 
 
(140,483
)
Segment loss
 
 
(302,831
)
 
(87,823
)
 
(390,654
)
 
(419,186
)
 
(809,840
)
Segment assets (1)
 
 
234,793
 
 
1,413,772
 
 
1,648,565
 
 
1,281,703
 
 
2,930,268
 
   
(1)
Segment assets have been adjusted for intercompany accounts to reflect actual assets for each segment.

The table below presents certain financial information by business segment for the nine months ended September 30, 2005.

 
 
Safety and Security
 
Information Management
 
Segments Total
 
Corporate
 
Consolidated Total
 
Revenue from external customers
 
$
209,972
 
$
311,247
 
$
521,219
 
 
-
 
$
521,219
 
Interest expense
 
 
-
 
 
(20,492
)
 
(20,492
)
 
(880,867
)
 
(901,359
)
Depreciation and amortization
 
 
(175,432
)
 
(214,928
)
 
(390,360
)
 
-
 
 
(390,360
)
Segment loss
 
 
(882,839
)
 
(760,964
)
 
(1,643,803
)
 
(1,897,834
)
 
(3,541,637
)

Note 10 - Subsequent Events
 







13


 
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS

FORWARD LOOKING STATEMENTS

Management’s Discussion and Analysis contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as historical information. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we can give no assurance that the expectations reflected in these forward-looking statements will prove to be correct. Forward-looking statements include those that use forward-looking terminology, such as the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “project,” “plan,” “will,” “shall,” “should,” and similar expressions, including when used in the negative. Although we believe that the expectations reflected in these forward-looking statements are reasonable and achievable, these statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Current shareholders and prospective investors are cautioned that any forward-looking statements are not guarantees of future performance. Such forward-looking statements by their nature involve substantial risks and uncertainties, certain of which are beyond our control, and actual results for future periods could differ materially from those discussed in this report, depending on a variety of important factors, among which are our ability to implement our business strategy, our ability to compete with major established companies, the acceptance of our products in our target markets, the outcome of litigation, our ability to attract and retain qualified personnel, our ability to obtain financing, our ability to continue as a going concern, and other risks described from time to time in our filings with the Securities and Exchange Commission. Forward-looking statements contained in this report speak only as of the date of this report. Future events and actual results could differ materially from the forward-looking statements. You should read this report completely and with the understanding that actual future results may be materially different from what management expects. We will not update forward-looking statements even though its situation may change in the future .

INTRODUCTION
 
The following discussion and analysis summarizes the significant factors affecting: (i) our consolidated results of operations for the three months and nine months ended September 30, 2006 compared to the three months and nine months ended September 30, 2005; and (ii) financial liquidity and capital resources.  This discussion and analysis should be read in conjunction with our consolidated financial statements and notes included in this Form 10-QSB. 

We are a biometric technology company specializing in biological identification security systems and web-based application services. Our business is divided into two operating segments: (a) Safety and Security; and (b) Information Management.

The use of unique physical traits to verify a person's identity is known as biometric identification. Biometric identification includes fingerprinting, hand geometry, iris scanning, retinal scanning, voice recognition, face recognition and signature analysis. Biometric technology has been used for decades in government and law enforcement applications. Until recently, these systems were too expensive to manufacture to make retail marketing realistic. However, due to the development of more advanced computers and software applications, we believe that biometric identification techniques can be adapted for retail and commercial purposes on an economically feasible basis. In addition, we believe that, as biometric technology becomes more familiar, that its use in safety and security applications will grow.

We believe that, although the biometric industry is in its infancy, biometric technology is a rapidly maturing science. Presently, although many companies have entered the biometric detection and application industry, many have failed to create marketable products.

We believe that fingerprint identification is more effective at authenticating a person's identity than other processes. We also believe that fingerprint verification is less intrusive, more widely accepted and more cost effective than other available forms of biometric identification, and as a result, we believe that the use of fingerprint identification biometrics for access control is becoming widely accepted in the marketplace.
 
We derive or plan to derive our revenues from five sources: (i) the sale and licensing of our biometric products; (ii) the sale and licensing of our software products; (iii) consulting, custom software services and web development services; (iv) maintenance agreements in connection with the sale and licensing of software products; and (v) internet access and web hosting services. Sales of biometric products are recognized upon delivery and completion of the sale. Software license revenue will be recognized when all of the following criteria have been met: (a) there is an executed license agreement and software has been delivered to the customer; (b) the license fee is fixed and payable within twelve months; (c) collection is deemed probable; and (d) product returns are deemed reasonably estimable. Maintenance revenues are recognized ratably over the term of the maintenance contract, typically 12 to 36 months. Internet access and web-hosting services are recognized over the period the services are provided, typically month-to-month.


14


The following table shows the proportion of total revenues by segment in the nine month period ended September 30, 2006.
 
Period
 
 
Safety and Security
 
 
Information Management
 
 
Total
 
Nine Months ended September 30, 2006
 
 
$
442,565
 
$
85,909
 
$
528,474
 
Results of Operations

The following table sets forth information regarding our financial results for the three and nine months ended September 30, 2006 and September 30, 2005.
 
 
For the Three Months Ended September 30,
 
For the Nine Months Ended September 30,
 
 
2006
2005
% Change
2006
2005
% Change
Revenue
$260,569
$322,843
-19%
$528,474
$521,219
1%
Costs of services and product sales
281,935
284,741
-1%
595,165
685,850
-13%
Selling, general and administrative
674,434
511,488
32%
2,678,292
2,321,548
15%
Gains on sale of equipment and restructuring of debt
-
-
-
(18,055)
(370)
-
Losses on impairment of intellectual properties and settlement of lawsuit
-
154,469
-
200,000
154,469
29%
Interest expense
846,927
181,985
365%
2,320,012
901,359
157%
Net loss
$(1,542,727)
$(809,840)
90%
$(5,246,940)
$(3,541,637)
48%

Quarter Ended September 30, 2006 compared to Quarter Ended September 30, 2005. Unless otherwise noted, references to 2006 represent the three-month period ended September 30, 2006 and references to 2005 represent the three-month period ended September 30, 2005.

Revenues. Total revenue decreased by $62,274 or 19% to $260,569 in 2006, from $322,843 in 2005. This decrease was due to a decrease in revenue from our Information Management segment of $177,945 or 86%. This decrease was partially offset by an increase in sales of biometric security products. Sales of biometric security products increased $115,671 or 99% from $116,700 in 2005 to $232,371 in 2006.

During the last few years we spent significant time acquiring and redeveloping our biometric technology products. As a result, we expect more significant sales of our biometric technology products to begin during the last three months of 2006 and thereafter. In addition to our own sales efforts we are looking for other companies in the industry to whom we can license our biometric technology products. We believe that this will result in an increase in the number of outlets in which these products are made available.

 

 
·
On September 13, 2005, Sequiam Corporation entered into a five-year, Exclusive Co-Operative Development and Supply Agreement with Black & Decker’s subsidiary Kwikset Corporation . The purpose of this agreement is to establish the business relationship between Kwikset and Sequiam in respect to the development, marketing and sales of biometric enabled security door hardware and systems.

 
·
Effective April 10, 2006, Sequiam Biometrics, Inc., a wholly-owned subsidiary of Sequiam Corporation, entered into an Exclusive License Agreement with Tacoma Technology, Inc. The purpose of this agreement is to provide the conditions and terms for the manufacturing and distribution of certain biometric products of Tacoma, including all of Tacoma’s biometric sensor modules. The term of this agreement is six years and may be automatically renewed for additional 24-month terms unless either party provides the other with 30-days prior notice of its desire not to renew.

 
·
Effective April 15, 2006, Sequiam Biometrics, Inc. entered into an Exclusive Distribution and Manufacturing Agreement with CJCC (China Jiangsu Construction Corporation). The purpose of this agreement is to provide the conditions and terms for the distribution of certain biometric products and services of Sequiam Biometrics, Inc., including a biometric personal digital assistant. The term of this agreement is five years and may be renewed for additional 24-month terms unless either party provides the other with written notice of termination at least 90 days prior to the expiration of the then current term.
 

15

 
·
On April 27, 2006, Sequiam Biometrics, Inc. , a wholly owned subsidiary of Sequiam Corporation, entered into a Joint Venture Agreement with Changjiang Computer Group Corporation and Magstone Innovation, Inc. . The name of the joint venture is Shanghai Changjiang Intelligence Information Technology, LTD . The joint venture is headquartered in Shanghai. The purpose of the joint venture agreement is to develop and market biometric and other information technology products and applications in China and other regions and to support Sequiam Biometrics, Inc. by providing research and development for new products. The joint venture agreement grants Sequiam Biometrics, Inc. exclusive rights to distribute those products in North America, Europe and Africa.

·  
Effective July 6, 2006, Sequiam Biometrics, Inc., a wholly-owned subsidiary of Sequiam Corporation, entered into a Distribution and Manufacturing Agreement with Quasar Group, Inc. The purpose of the agreement is to set out the terms and conditions of the distribution of certain biometric products and services of Sequiam Biometrics, Inc. Also, as part of the agreement, Sequiam Biometrics, Inc. and Quasar Group, Inc. agreed to form a new corporation in Switzerland. Sequiam Biometrics, Inc. will own 51% and Quasar Group, Inc. will own 49% of the new corporation. The new corporation agrees to purchase from Sequiam Biometrics, Inc., during the term of the agreement, all of its requirements as needed for its products for sale in Europe and the Middle East. In addition, Sequiam Biometrics, Inc. will act, during the term of the agreement, as the exclusive biometric designer and manufacturer of products for the new corporation. The term of the agreement is ten years, expiring on July 6, 2016, and may be renewed for additional 24-month terms unless either party provides the other with written notice of termination at least twelve months prior to the expiration of the then current term.
 
As a result of these developments, we expect: (a) that consulting, custom software services, web development and web-hosting activities will make up a much smaller portion of our overall revenues; and (b) that revenues from our Safety and Security segment will continue to increase during the last quarter of 2006 and thereafter as we focus our efforts on our biometric products.

Cost of Services and Product Sales. Cost of services and product sales were $281,935 in 2006 and $284,741 in 2005, a decrease of $2,806 or 1%. This slight decrease was attributable to a decrease in the amount of depreciation and amortization expense allocated to cost of services and product sales from $140,482 in 2005 to $91,698 in 2006, a decrease of $48,784. This decrease was partially offset by an increase in biometric security product related costs.

Selling, General and Administrative. Selling, general and administrative expenses were $674,434 in 2006 and $511,488 in 2005, an increase of $162,946, or 32%. The increase was attributed to an overall increase in payroll from $246,043 in 2005 to $303,049 in 2006, an increase of $57,006, or 23%, an increase in business travel from $20,812 in 2005 to $44,438 in 2006, an increase of $23,626, an increase in depreciation allocated to selling, general and administrative expenses of $42,613 and an increase in non-payroll related expenses incurred by Constellation Biometrics Corporation, who we acquired during the second quarter of 2005, from $10,204 in 2005 to $29,906 in 2006, an increase of $19,702.
 

Interest Expense. Interest expense was $846,927 in 2006 and $181,985 in 2005, an increase of $664,942, or 365%. This increase was due to an increase in the non-cash charge which resulted from the accretion of the debt discount related to the fair value of warrants for common stock issued in connection with various loan agreements and mandatorily redeemable cumulative convertible preferred stock. The increase was partially offset by write-offs of loan costs and debt discounts during 2005 that were a result of the refinancing of certain debt.

Net Losses. We incurred net losses of $1,542,727 in 2006 and $809,840 in 2005, an increase of $732,887 or 90%. The increase was due to a $62,274 decrease in revenues, a $162,946 increase in selling, general and administrative expenses and a $664,942 increase in interest expense. The increase was partially offset by the loss on the impairment of intellectual properties of $154,469 recognized in 2005. We expect to incur additional net losses through the fourth quarter of 2006 as we continue to produce our biometrics products. We expect our cash flow to improve beginning in the fourth quarter of 2006 using proceeds from the sales of our biometric products. We currently estimate monthly sales of approximately $600,000 with gross margins averaging 60% or $350,000 per month are required to provide a positive cash flow.

Nine Months Ended September 30, 2006 compared to Nine Months Ended September 30, 2005. Unless otherwise noted, references to 2006 represent the nine-month period ended September 30, 2006 and references to 2005 represent the nine-month period ended September 30, 2005.

16

Revenues. Total revenue increased $7,255 or 1% to $528,474 in 2006 from $521,219 in 2005. This was due to an increase in sales of biometric security products from $209,972 in 2005 to $442,565 in 2006, an increase of $232,593. Included in biometric security product sales are the sales from Constellation Biometrics Corporation, which we acquired during the second quarter of 2005. Constellation’s 2006 sales were $278,237 compared to 2005 sales of $97,682, an increase of $180,555. The increase in total revenue that resulted from the increase in sales of biometric security products was partially offset by a $225,338 decrease in revenues earned by our Information Management segment during 2006, as compared to 2005. This decrease resulted from a shift in primary focus from our Information Management segment to our Safety and Security segment.

Cost of Services and Product Sales. Cost of services and product sales were $595,165 in 2006 and $685,850 in 2005, a decrease of $90,685 or 13%. This decrease was primarily attributable to a decrease in the amount of depreciation and amortization expense allocated to cost of services and product sales from $390,362 in 2005 to $263,663 in 2006, a decrease of $126,699.

Selling, General and Administrative. Selling, general and administrative expenses were $2,678,292 in 2006 and $2,321,548 in 2005, an increase of $356,744 or 15%. The was primarily due to an increase in payroll from $852,898 in 2005 to $1,185,673 in 2006, an increase of $332,775, an increase in non-payroll related expenses incurred by Constellation Biometrics Corporation, who we acquired during the second quarter of 2005, from $15,423 in 2005 to $131,746 in 2006 and an increase in the amount of amortization and depreciation expense allocated to selling, general and administrative expenses of $87,662. The increase was partially offset by an overall decrease in selling, general and administrative expenses not related to payroll, Constellation or depreciation. This decrease was attributed to non-cash and non-recurring 2005 expenses for investment banking, consulting and other non-payroll expenses acquired in exchange for stock.
 
As discussed above, our total payroll included in selling, general and administrative expenses was $1,185,673 for 2006 and $852,898 for 2005, an increase of $332,775 or 39%. This increase was due to: (a) $282,269 of payroll expense recognized during 2006 as a result of issuing shares of our common stock to our CEO and CFO in order to pay salaries due to them; (b) the hiring of additional employees in our Safety and Security segment beginning during the latter part of 2005; (c) the hiring of an employee during the first quarter of 2006 to assist with corporate accounting and financial reporting responsibilities; and (d) the addition during the second quarter of 2005 of employees due to the acquisition of Constellation Biometrics Corporation. The increase was partially offset by a decrease in payroll related to our Information Management segment that resulted from the change in our primary focus from the Information Management segment to the Safety and Security segment.
 
Gains on sale of equipment and restructuring of debt. During 2006 we recognized a gain on sale of equipment of $5,000 and a gain on restructuring of debt of $13,055. The gain on sale of equipment was recognized when we received $5,000 for a piece of our equipment that was fully depreciated and no longer used in our operations. The gain on restructuring of debt represented the write-down of a note payable to the amount that was repaid to the lender, which was agreed to by the lender.
 
Losses on impairment of intellectual properties and settlement of lawsuit. A loss of $154,469 was recognized on the impairment of intellectual properties in 2005. A loss on settlement of a lawsuit of $200,000 was recognized during 2006. On July 13, 2006, we reached an agreement with Chapman Spira & Carson, LLC to settle the complaint filed by Chapman on or about September 28, 2005 in United States District Court for the Southern District of New York in which Chapman asserted claims for breach of contract and unjust enrichment. The agreement to settle the dispute required us to deliver a cash payment to Chapman of $200,000. This cash payment was made in July 2006.

Interest Expense. Interest expense was $2,320,012 in 2006 and $901,359 in 2005, an increase of $1,418,653 or 157%. This increase was due to: (a) a non-cash charge of $224,386 which resulted from the issuance of 7,056,712 shares of our common stock to our CEO and CFO during 2006 that served as payment of accrued salaries and interest due them; and (b) a non-cash charge of $101,970 that resulted from an amendment to a promissory note that modified the terms of warrants granted under the original promissory note. The increase was also a result of an increase in the non-cash charge which resulted from the accretion of the debt discount related to the fair value of warrants for common stock issued in connection with the various loan agreements and mandatorily redeemable cumulative convertible preferred stock. The total accretion of debt discounts during 2006 was $1,503,378 compared to $485,228 during 2005, and increase of $1,018,150.

Net Losses. We incurred net losses of $5,246,940 in 2006 and $3,541,637 in 2005, an increase of $1,705,303 or 48%. The increase was due to a $356,744 increase in selling, general and administrative expenses and an increase in interest expense of $1,418,653. The increase was partially offset by a $97,940 improvement in revenues and cost of revenues.

Liquidity and Capital Resources

General
 
Our principal use of cash in our operating activities is for inventory and selling general and administrative expenses.  Our principal source of liquidity has historically been from financing activities. We expect our cash flow to improve during the fourth quarter of 2006 as a result of the sales of our biometric products.

17

 Operating Activities

Net cash used for operating activities was $2,681,358 for 2006, as a result of the net loss during the period of $5,246,940 and an increase in inventory of $779,451, offset by non-cash expenses of $2,793,176, and an increase in accounts payable of $509,978.

Investing and Financing Activities

Net cash used for investing activities for 2006 was $274,948, consisting primarily of product development costs of $192,500 and equipment purchases of $87,448.

Net cash provided by financing activities for 2006 was $2,209,273, representing proceeds from the sale of common stock and exercise of warrants of $250,000 and proceeds from the sale of preferred stock of $2,962,500, offset by the payment of stock issuance costs of $347,181, the repayment of notes payable of $20,000 and the repayment of long-term debt of $635,398.


We anticipate product sales increasing in 2006 to where they will sustain our existing operations.

We have been able, thus far, to finance our net losses, as well as the growth of the business, primarily through debt and stock offerings. We are continuing to seek other sources of financing and attempting to increase revenues within our core business of biometric security products. There are no assurances that we will be successful in achieving our goals.
 
In view of these conditions, our ability to continue as a going concern is dependent upon our ability to obtain additional financing or capital sources, to meet our financing requirements, and ultimately to achieve profitable operations. We believe that our current and future plans provide an opportunity to continue as a going concern. The condensed consolidated financial statements included in this Form 10-QSB do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event we cannot continue as a going concern.

Application of Critical Accounting Policies

We utilize certain accounting policies and procedures to manage changes that occur in our business environment that may affect accounting estimates made in preparation of our financial statements. These estimates relate primarily to our allowance for doubtful accounts receivable and the recognition and measurement of potential impairment on long-lived and intangible assets. Our strategy for managing doubtful accounts includes stringent, centralized credit policies and collection procedures for all customer accounts. We utilize a credit risk rating system in order to measure the quality of individual credit transactions. We strive to identify potential problem receivables early, take appropriate collection actions, and maintain adequate reserve levels. Management reviews its long-lived and intangible assets for impairment whenever changes in circumstances or other events indicate potential impairment. Management has determined that the allowance for doubtful accounts and impairment losses are adequate at September 30, 2006.

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.
 
ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined by Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission (the “SEC”) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to the Company's management. Based on their most recent evaluation, which was completed during the period covered by this report, the Company's Chief Executive Officer and Chief Financial Officer concluded that: (a) the Company's disclosure controls and procedures are effective, to give reasonable assurance that the information required to be disclosed by the Company in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (b) the Company’s disclosure controls and procedures are also effective to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
 
18

Changes in Internal Control Over Financial Reporting

In addition, management, including the Company's Chief Executive Officer and Chief Financial Officer, reviewed the Company's “internal control over financial reporting” (as defined by Rule 15(d)-15(f) of the Exchange Act), and there have been no changes in the Company's internal control or in other factors that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting during the period covered by this report.
 
PART II: OTHER INFORMATION
 
ITEM 1 - LEGAL PROCEEDINGS

On July 13, 2006, the Company reached an agreement with Chapman Spira & Carson, LLC (“Chapman”) to settle the complaint filed by Chapman on or about September 28, 2005 in United States District Court for the Southern District of New York in which Chapman asserted claims for breach of contract and unjust enrichment (the “Dispute”). The agreement to settle the Dispute required the Company to deliver a cash payment to Chapman of $200,000, which was made in July 2006. As a result, the Company recorded a loss on settlement of lawsuit of $200,000 during the nine months ended September 30, 2006. In exchange for the settlement payment, both parties stipulated and agreed that all claims and counterclaims in the Dispute are discontinued as to all parties with prejudice. Neither party admitted any liability or wrongdoing and the settlement did not construe any admission of liability or wrongdoing.
 
 
During the three months ended September 30, 2006, the following activity occurred related to the Company’s capital stock:

During the period covered by this Report, the Company issued an aggregate of 4,076,190 of its common shares as a result of elections made by holders of the Company’s mandatorily redeemable cumulative convertible preferred stock to convert shares of the Company’s Series A preferred stock to shares of the Company’s common stock, at a fixed conversion rate of $0.21 per share. Also, the Company issued 301,612 of its common shares to the holders of the Company’s mandatorily redeemable cumulative convertible preferred stock as payment of the 9% cumulative dividend payable to Series A preferred stockholders. Because no commission or other remuneration was paid or given directly or indirectly for soliciting the aforementioned exchanges, the conversions described above were exempt from registration pursuant to Section 3(a)(9) of the Securities Act.


(a) Exhibits:

31.1
Certification of Chief Executive Officer Pursuant To 15d-14.*
31.2
Certification of Chief Financial Officer Pursuant To 15d-14.*
32.1
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350.*
32.2
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350.*
 

 
* Filed herewith





19



 
SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SEQUIAM CORPORATION


Date: November 14, 2006

By: /s/ Nicholas H. VandenBrekel                        
Nicholas H. VandenBrekel, President and Chief Executive Officer


Date: November 14, 2006

By: /s/ Mark L. Mroczkowski                                
Mark L. Mroczkowski, Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer) 
 

20